Regorafenib: Carving a niche in the crowded therapeutic landscape

Expert Review of Anticancer Therapy

Volumn 13, Issue 4, 2013, Pages 385-393

  Sirohi, Bhawna ^a   Philip, Deepa Susan ^a   Shrikhande, Shailesh V ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

multikinase inhibitor; Phase III data; regorafenib; targeted therapy

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; KETOCONAZOLE; MIDAZOLAM; OMEPRAZOLE; OXALIPLATIN; PEMETREXED; PHARMACOLOGICAL BIOMARKER; PLACEBO; REGORAFENIB; RIFAMPICIN; ROSIGLITAZONE; SORAFENIB; WARFARIN;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FATIGUE; FOOD; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; LIPID DIET; LIVER FAILURE; LOW FAT DIET; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; VOICE; VOMITING;

COLORECTAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PHENYLUREA COMPOUNDS; PROGNOSIS; PYRIDINES;

EID: 84876139129     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.12     Document Type: Article

References (36)

1. Grothey A, Van Cutsem E, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303-312 (2013)
2. Van Cutsem EJD, Grothey A, Sobrero A et al. Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (MCRC): overall survival update. Ann. Oncol. LBA18 (2012)
3. Demetri GD, Reichardt P, Kang YK et al.; GRID Study Investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 295-302 (2013)
4. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000)
5. Seymour MT, Maughan TS, Ledermann JA et al.; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582), 143-152 (2007)
6. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000)
7. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229-237 (2004)
8. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised Phase III trials. Brit. J. Cancer 90, 1190-1197 (2004)
9. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135-142 (2007)
10. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22(7), 1209-1214 (2004)
11. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138), 1407-1412 (1998)
12. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499-3506 (2012)
13. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013-2019 (2008)
14. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008)
15. Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706-4713 (2010)
16. Folkman J. Angiogenesis. Annu. Rev. Med. 57, 1-18 (2006)
17. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971
18. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245-255 (2011)
19. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004)
20. Mross K, Frost A, Steinbild S et al. A Phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 18(9), 2658-2667 (2012)
21. Hedbom S, Steinbild S, Frost A et al. Phase I study of BAY 73-4506, amultikinase inhibitor, administered for 21 days on/7 days off in patients withadvanced solid tumors. J. Clin. Oncol. 25(18S), Abstract 3593 (2007)
22. Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase I study. Br. J. Cancer 106(11), 1722-1727 (2012)
23. Zopf D, Heinig R, Thierauch KH et al. Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. Presented at: American Association for Cancer Research 101st Annual Meeting. Washington, DC, USA, 17-21 April 2010.
24. Shimizu T, Tolcher AW, Patnaik A et al. Phase I dose-escalation study ofcontinuously administered regorafenib(BAY 73-4506), an inhibitor ofoncogenic and angiogenic kinases, inpatients withadvanced solid tumors. J. Clin. Oncol. 28(15S), Abstract 3035 (2010)
25. Eisen T, Joensuu H, Nathan P et al. Phase II trial of the oral multikinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). Eur. J. Cancer 47, 7141 (2011)
26. Eisen T, Joensuu H, Nathan PD et al. Regorafenib for patients with previously untreated metastatic or unresectable Renal cell carcinoma: a single-group Phase 2 trial. Lancet Oncol. 13(10), 1055-1062 (2012)
27. George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter Phase II trial. J. Clin. Oncol. 30(19), 2401-2407 (2012)
28. Schultheis B, Folprecht G, Kuhlmann J et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second line colorectal cancer. J. Clin. Oncol. 29, Abstract 3585 (2011)
29. Reichardt P, Casali PG, Kang YK et al. Clinical benefit with regorafenib across subgroups and post-progression in patients with advanced gastrointestinal stromal tumor after progression on imatinib and sunitinib: Phase 3 GRID trial update, 2012 ESMO Congress. Abstract 14780 (2012)
30. Masi G, Loupakis F, Salvatore L et al. A randomised Phase III study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment. Results of the BEBYP trial by the Gruppo Oncologico Nord Ovest. ESMO Congress. Abstract LBA17 (2012)
31. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a Phase II prospective trial. J. Clin. Oncol. 28(1), 8-14 (2010)
32. Jeffers M, Quinn D, Joensuu H et al. Identification of plasma biomarkers for the multikinase inhibitor regorafenib (BAY 73-4506) in patients (pts) with renal cell cancer (RCC). Ann. Oncol. 21, 1238 (2010)
33. O'Connor JP, Jackson A, Parker GJ et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat. Rev. Clin. Oncol. 9, 167-177 (2012)
34. Van Den Abbeele AD, Tanaka Y, Locascio T et al. Assessment of regorafenib activity with FDG-PET/CT in a multicenter Phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). J. Clin. Oncol. 29, Abstract 10050 (2011)
35. Highlights of Prescribing Information. www.accessdata.fda.gov/drugsatfda- docs/ label/2012/203085lbl.pdf
36. ClinicalTrials.gov. http://clinicaltrials.gov/